Aethlon Medical, Inc.

Good day and welcome to the Act On Medical Fiscal Year End 2022 Earnings and Corporate Update Conference Call. All participants will be in less than only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw from the question queue, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Jim Frakes, Chief Financial Officer. Please go ahead.

Thank you, Operator, and good afternoon, everyone. Welcome to Athlon Medical's fiscal year-end conference call. My name is Jim Frakes, and I'm Athlon's Chief Financial Officer. At 4.15 p.m. Eastern Time today, Athlon Medical released financial results for its fiscal year ended March 31, 2023. If you have not seen or received Athlon Medical's earnings release, please visit the investors page at www.athlonmedical.com. Following this introduction and the reading of our forward-looking statement, Athlon's Chief Medical Officer, Dr. Steven LaRosa, will provide an overview of Athlon's strategy and recent developments. I will then make some brief remarks on Athlon's financials. We will then open up the call for the Q&A session. Now, before I hand the call over to Dr. La Rosa, please note that the news released today and this call contain forward-looking statements in the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The company cautions you that any statement that is not a statement of historical fact is a forward-looking statement. These statements are based on expectations and assumptions as of the date of this conference call. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption risk factors in the company's annual report on Form 10-K for the fiscal year ended March 31, 2023, our most recent report on Form 10-Q, and in the company's other filings with the Securities and Exchange Commission. Except as may be required by law, the company does not intend nor does it undertake any duty to update this information to reflect future events or circumstances. With that, I will now turn the call over to Dr. Steven LaRosa, Athlon's Chief Medical Officer.

Thank you, Jim, and thank all of you for dialing in. This is Steve LaRosa, the Chief Medical Officer at Athlon Medical. Athlon Medical is continuing the research and clinical development of its hemopurifier, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from the blood. This action has potential applications in cancer, where cancer-associated exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The company's ongoing COVID-19 trial in India for patients in the Intensive Care Unit at Medanta Medicity Hospital remains open for enrollment, with one patient treated to date. In May 2023, A second clinical site, Malana Azad Medical College, MAMC, received ethics board approval to participate in the trial, and site activation activities are currently underway. Cases of COVID-19 infection that require hospitalization continue to occur in India. The addition of MAMC as a second high-quality clinical site may improve the enrollment of patients who go on to require ICU care for their severe COVID infection. In the oncology indication, Athlon Medical continues to work with its contract research organization, NAMSA, to initiate a clinical trial in Australia. This new clinical trial in oncology is planned to be a safety, feasibility, and dose-finding trial in solid tumors failing anti-PD1 antibodies. Management of Athlon Medical believes that the data from this trial will help inform the design of future efficacy trials of the company's hemopurifier in oncology. Current activities underway for this trial would include site identification and qualification, finalization of the necessary documents for ethics board submission at the clinical sites, case report form development, and selection of a data safety monitoring board. On June 21, 2023, Athlon announced that it is investigating the use of its hemopurifier in the organ transplant market. Specifically, the company is conducting translational studies with the objective of determining if the hemopurifier when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes from harvested organs. The company has previously demonstrated the removal of multiple viruses and exosomes from buffer solutions in vitro using a scaled-down version of the hemopurifier. This process may potentially reduce complications following transplantation of a harvested organ, including viral infection, delayed graft function, and rejection. The company believes that this new approach could be additive to existing therapies that are currently in place to increase the number of viable organs for transplant. According to precedent's research, the size of the global organ transplantation market is projected to hit approximately $33.7 billion by 2032, compared to $15.1 billion in 2022. Further, precedent research estimates that the global organ transplantation market is poised to expand at a compounded average growth rate of 8.36 percent during the forecast period of 2023 through 2032. Additionally, according to precedence research, rising demand for organ transplantation to treat organ failure and novel tissue transplantation products is the prime factor that is driving this market growth. In the United States, all organ transplant programs must be located in hospitals that have a Medicare provider agreement. The ultimate goal of Athlon's medical research in the organ transplantation area is to position the hemopurifier as a beneficial and potentially transformative accessory element to existing or future organ perfusion systems to keep harvested organs in transplantable condition. Now, with that, I will turn it over to Jim for the financial discussion and then open up for questions.